GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms E Walmsley |
|||
b) |
Position/status |
Chief Executive Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
26 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr R Connor |
|||
b) |
Position/status |
President, Global Vaccines |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
80 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms D Conrad |
|||
b) |
Position/status |
SVP, Human Resources |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
2 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr N Hirons |
|||
b) |
Position/status |
SVP, Global Ethics & Compliance |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
18 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms S Jackson |
|||
b) |
Position/status |
SVP, Global Communications and CEO Office |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
73 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr D Jackson |
|||
b) |
Position/status |
PCA of Ms S Jackson (SVP, Global Communications and CEO Office) |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
27 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr L Miels |
|||
b) |
Position/status |
President, Global Pharmaceuticals |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
5 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr D Redfern |
|||
b) |
Position/status |
Chief Strategy Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
90 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr R Simard |
|||
b) |
Position/status |
President, Pharmaceuticals Supply Chain |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
27 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Mr P C Thomson |
|||
b) |
Position/status |
President, Global Affairs |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
52 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms D Waterhouse |
|||
b) |
Position/status |
Chief Executive Officer of ViiV Healthcare |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
71 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Ms V Whyte |
|||
b) |
Position/status |
Company Secretary |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GlaxoSmithKline plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2020, on shares held through the Company's Share Reward Plan. |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.2576 |
66 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction)
|
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2020-10-08 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |